Hyloris Pharmaceuticals financials
Hyloris Pharmaceuticals
875500LZIWS7QEQE0I73 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €7.2M | €8.5M |
| Cost of sales | €379.0K | €227.0K |
| Operating expenses | €15.6M | €17.2M |
| Operating profit (EBIT) | -€6.8M | -€7.1M |
| Finance costs | €739.0K | €378.0K |
| Profit before tax | -€6.7M | -€6.3M |
| Income tax expense | -€374.0K | €0 |
| Profit for the year | -€6.3M | -€6.3M |
| — attributable to owners | -€6.3M | -€6.3M |
| Total comprehensive income | -€6.3M | -€6.3M |
| Per share | ||
| Basic EPS | €-0.23 | €-0.23 |
| Diluted EPS | €-0.23 | €-0.23 |
| Free cash flow / share | €-0.25 | €-0.26 |
| Cash flow statement | ||
| Net cash from operating activities | -€7.0M | -€7.2M |
| Net cash from investing activities | -€2.1M | €683.0K |
| Purchase of PP&E (capex) | €4.0K | €30.0K |
| Purchase of intangibles | €625.0K | €268.0K |
| Net cash from financing activities | -€406.0K | -€420.0K |
| Proceeds from borrowings | €0 | €139.0K |
| Repayments of borrowings | €0 | €218.0K |
| Lease liability payments | €339.0K | €264.0K |
| Balance sheet | ||
| Total assets | €33.4M | €41.3M |
| Non-current assets | €13.4M | €11.6M |
| Property, plant & equipment | €225.0K | €340.0K |
| Right-of-use assets | €1.5M | €1.7M |
| Current assets | €20.0M | €29.7M |
| Inventories | €52.0K | €0 |
| Trade & other receivables | €5.2M | €4.9M |
| Cash & equivalents | €13.8M | €23.6M |
| Total equity | €26.5M | €32.1M |
| Non-current liabilities | €1.7M | €2.0M |
| Long-term borrowings | €1.2M | €1.5M |
| Current liabilities | €5.1M | €7.2M |
| Short-term borrowings | €364.0K | €326.0K |
| Trade & other payables | €4.7M | €3.4M |
| Derived metrics | ||
| Free cash flow | -€7.0M | -€7.2M |
| Operating margin | -94.5% | -84.3% |
| Net margin | -87.9% | -75.0% |
| Return on equity | -23.9% | -19.7% |
| Cash conversion ratio | 1.10× | 1.13× |
| Capex coverage | -1747.25× | -239.73× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€52.0K | €0 |
| Adjustments For Decrease Increase In Other Operating Receivables | €66.0K | €403.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€273.0K | -€2.3M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €919.0K | €648.0K |
| Adjustments For Finance Income Cost | €332.0K | €904.0K |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | -€71.0K | -€81.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€435.0K | €140.0K |
| Adjustments For Provisions | -€385.0K | €581.0K |
| Adjustments For Sharebased Payments | €665.0K | -€584.0K |
| Current Provisions | €75.0K | €408.0K |
| Current Tax Assets Current | €362.0K | €508.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€300.0K | €117.0K |
| Equity and Liabilities | €33.4M | €41.3M |
| Finance Income | €840.0K | €1.2M |
| General and Administrative Expense | €4.9M | €5.6M |
| Increase Decrease In Cash and Cash Equivalents | -€9.5M | -€6.9M |
| Increase Decrease Through Sharebased Payment Transactions | €666.0K | -€584.0K |
| Intangible Assets Other Than Goodwill | €5.7M | €3.8M |
| Interest Paid Classified As Financing Activities | €67.0K | €77.0K |
| Interest Received Classified As Investing Activities | €399.0K | €981.0K |
| Investment Accounted For Using Equity Method | €2.5M | €2.7M |
| Issued Capital | €140.0K | €140.0K |
| Liabilities | €6.9M | €9.2M |
| Miscellaneous Other Operating Income | €1.6M | €1.6M |
| Noncurrent Provisions | €416.0K | €473.0K |
| Noncurrent Receivables | €2.5M | €2.0M |
| Other Adjustments For Noncash Items | €252.0K | -€106.0K |
| Other Comprehensive Income | €0 | €0 |
| Other Current Financial Assets | €492.0K | €556.0K |
| Other Current Financial Liabilities | €0 | €3.0M |
| Other Current Nonfinancial Assets | €125.0K | €191.0K |
| Other Noncurrent Financial Assets | €1.0M | €1.0M |
| Other Noncurrent Financial Liabilities | €87.0K | €68.0K |
| Other Reserves | -€2.4M | -€3.0M |
| Research and Development Expense | €11.3M | €10.3M |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€92.8M | -€86.5M |
| Revenue and Operating Income | €8.8M | €10.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -€71.0K | -€81.0K |
| Share Premium | €121.5M | €121.5M |
Every line item above is a fact tagged in Hyloris Pharmaceuticals's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.